Neutropenia and agranulocytosis in England and Wales: incidence and risk factors.

The objectives of this study were to estimate the incidence of idiosyncratic neutropenia and agranulocytosis in England and Wales and to evaluate their risk factors and outcomes. The study was conducted using data from the General Practice Research Database. All cases of idiosyncratic neutropenia or...

Full description

Bibliographic Details
Main Authors: van Staa, T, Boulton, F, Cooper, C, Hagenbeek, A, Inskip, H, Leufkens, H
Format: Journal article
Language:English
Published: 2003
_version_ 1826265981351100416
author van Staa, T
Boulton, F
Cooper, C
Hagenbeek, A
Inskip, H
Leufkens, H
author_facet van Staa, T
Boulton, F
Cooper, C
Hagenbeek, A
Inskip, H
Leufkens, H
author_sort van Staa, T
collection OXFORD
description The objectives of this study were to estimate the incidence of idiosyncratic neutropenia and agranulocytosis in England and Wales and to evaluate their risk factors and outcomes. The study was conducted using data from the General Practice Research Database. All cases of idiosyncratic neutropenia or agranulocytosis were identified and the incidence was estimated. This was followed by a nested case-control study, estimating odds ratios with drug exposure from conditional logistic regression. From 1987 to 1999, 3,224 patients with idiosyncratic neutropenia (50 with agranulocytosis) were identified. The incidences of neutropenia and agranulocytosis were estimated to be 120 and 7 cases per million people per year, respectively. The adjusted odds ratios for neutropenia were 34.7 (95% confidence interval 12.0-99.7) for current users of thyroid inhibitors, 9.5 (4.4-20.8) for users of disease-modifying antirheumatic drugs, and 7.6 (4.9-11.9) for users of aminosalicylates. Other drugs with statistically significantly increased risks of neutropenia included antibacterial drugs, non-opioid analgesics, NSAIDs, antidepressants, ulcer-healing drugs, and anti-epileptics. The increase in risk of neutropenia predominantly occurred during the first months of treatment. For most drugs investigated in this study, there was no relationship to daily dose. The excess 1-year mortality was low among neutropenia and agranulocytosis cases and mostly explained by the underlying disease state. In conclusion, the highest risks of neutropenia were generally found in patients starting treatment. The excess 1-year mortality was low among neutropenia and agranulocytosis cases and can be mostly explained by the underlying disease state.
first_indexed 2024-03-06T20:32:02Z
format Journal article
id oxford-uuid:3160d519-9770-41c8-a318-e6b497630343
institution University of Oxford
language English
last_indexed 2024-03-06T20:32:02Z
publishDate 2003
record_format dspace
spelling oxford-uuid:3160d519-9770-41c8-a318-e6b4976303432022-03-26T13:07:40ZNeutropenia and agranulocytosis in England and Wales: incidence and risk factors.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3160d519-9770-41c8-a318-e6b497630343EnglishSymplectic Elements at Oxford2003van Staa, TBoulton, FCooper, CHagenbeek, AInskip, HLeufkens, HThe objectives of this study were to estimate the incidence of idiosyncratic neutropenia and agranulocytosis in England and Wales and to evaluate their risk factors and outcomes. The study was conducted using data from the General Practice Research Database. All cases of idiosyncratic neutropenia or agranulocytosis were identified and the incidence was estimated. This was followed by a nested case-control study, estimating odds ratios with drug exposure from conditional logistic regression. From 1987 to 1999, 3,224 patients with idiosyncratic neutropenia (50 with agranulocytosis) were identified. The incidences of neutropenia and agranulocytosis were estimated to be 120 and 7 cases per million people per year, respectively. The adjusted odds ratios for neutropenia were 34.7 (95% confidence interval 12.0-99.7) for current users of thyroid inhibitors, 9.5 (4.4-20.8) for users of disease-modifying antirheumatic drugs, and 7.6 (4.9-11.9) for users of aminosalicylates. Other drugs with statistically significantly increased risks of neutropenia included antibacterial drugs, non-opioid analgesics, NSAIDs, antidepressants, ulcer-healing drugs, and anti-epileptics. The increase in risk of neutropenia predominantly occurred during the first months of treatment. For most drugs investigated in this study, there was no relationship to daily dose. The excess 1-year mortality was low among neutropenia and agranulocytosis cases and mostly explained by the underlying disease state. In conclusion, the highest risks of neutropenia were generally found in patients starting treatment. The excess 1-year mortality was low among neutropenia and agranulocytosis cases and can be mostly explained by the underlying disease state.
spellingShingle van Staa, T
Boulton, F
Cooper, C
Hagenbeek, A
Inskip, H
Leufkens, H
Neutropenia and agranulocytosis in England and Wales: incidence and risk factors.
title Neutropenia and agranulocytosis in England and Wales: incidence and risk factors.
title_full Neutropenia and agranulocytosis in England and Wales: incidence and risk factors.
title_fullStr Neutropenia and agranulocytosis in England and Wales: incidence and risk factors.
title_full_unstemmed Neutropenia and agranulocytosis in England and Wales: incidence and risk factors.
title_short Neutropenia and agranulocytosis in England and Wales: incidence and risk factors.
title_sort neutropenia and agranulocytosis in england and wales incidence and risk factors
work_keys_str_mv AT vanstaat neutropeniaandagranulocytosisinenglandandwalesincidenceandriskfactors
AT boultonf neutropeniaandagranulocytosisinenglandandwalesincidenceandriskfactors
AT cooperc neutropeniaandagranulocytosisinenglandandwalesincidenceandriskfactors
AT hagenbeeka neutropeniaandagranulocytosisinenglandandwalesincidenceandriskfactors
AT inskiph neutropeniaandagranulocytosisinenglandandwalesincidenceandriskfactors
AT leufkensh neutropeniaandagranulocytosisinenglandandwalesincidenceandriskfactors